Drug Profile
AL 102
Alternative Names: AL-102; BMS 986115; WHG-626Latest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Ayala Pharmaceuticals; Bristol-Myers Squibb; Novartis
- Class Amides; Antineoplastics; Benzene derivatives; Benzodiazepines; Fluorinated hydrocarbons; Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Fibroma
- Phase I Multiple myeloma
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Mar 2024 Ayala Pharmaceuticals announces intention to submit an NDA application for AL 102
- 26 Mar 2024 Immunome acquires AL 102 from Ayala Pharmaceuticals
- 28 Feb 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Australia (PO)